Perinatal motor function loss in human spina bifida aperta
PhD ceremony: Ms. R.J. Verbeek, 16.15 uur, Academiegebouw, Broerstraat 5, Groningen
Dissertation: Perinatal motor function loss in human spina bifida aperta
Promotor(s): prof. O.F. Brouwer
Faculty: Medical Sciences
We studied the initiation and evolvement of segmental neuromuscular damage in children with myelomeningocele, the severe variant of a congenital neural tube defect or spina bifida aperta (SBA). Therefore, we measured muscle ultrasound density (MUD) in association with leg motor function loss both before and after birth. Results confirm the existence of two different impacts upon the segmental neurological leg-condition: 1. ‘congenital’ damage as a direct consequence of the MMC, and 2. delayed, perinatal damage by secondary spinal trauma. The results indicating delivery-related spinal segmental haemorrhages located near persistent lower motor neurons, might explain the early neonatal disappearance of leg movements. This secondary perinatal segmental spinal damage, superimposed upon the congenital MMC, is hypothetically referred to as the ‘second-hit’ of spinal damage. During the first year of life, the evolution of SBA leg MUD alterations reflects the impact of both ‘congenital’ and ‘second-hit’ spinal damage upon leg muscle integrity. Afterwards (1-18 years) leg-MUD parameters reflect a ‘stabilised’ neuromuscular leg condition (i.e. completion of ‘second-hit’ damage). Fetal closure of the MMC might protect aberrant blood vessels from bleeding and preserve neurological function. We found that fetal endoscopic surgery is associated with better spinal neuroprotection than neonatal surgery, but this is at the cost of iatrogenic morbidity for mother and child. Before considering clinical implementation of fetal MMC treatment as standard care, the frequency and impact of these complications should be reduced and investigated in larger study groups over a longer period of time.
Last modified: | 13 March 2020 12.59 a.m. |
More news
-
27 August 2024
UMCG gaat onderzoeksfaciliteiten beschikbaar stellen voor geneesmiddelenontwikkeling
Om de beschikbaarheid en effectiviteit van geneesmiddelen in Nederland te verbeteren gaat het UMCG het bedrijf G² Solutions opzetten. Dit bedrijf moet ervoor gaan zorgen dat belangrijke technologische ontwikkelingen op het gebied van DNA sequencing...
-
17 July 2024
Veni-grants for ten researchers
The Dutch Research Council (NWO) has awarded a Veni grant of up to €320,000 each to ten researchers of the University of Groningen and the UMCG. The Veni grants are designed for outstanding researchers who have recently gained a PhD.
-
16 July 2024
Medicine still subjects to male bias
Aranka Ballering studied the course of illness in people with common symptoms. One of the most striking findings to emerge from her research was that on average, women have a different – and less extensive – course of illness than men.